Assembly Biosciences Inc. Common Stock (ASMB)

FairStock Score: 57/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses with honest profits and a margin of safety. Assembly Biosciences is not that yet: it is a 73-employee clinical-stage antiviral company with Phase 1 candidates, no approved product, and a Lynch screen that assigns no category because it has lost money in each of the last four years. The trend is improving, though. In fiscal year 2025, the period ended 2025-12-31, revenue was $72.3M and net income was -$6.1M, compared with $28.5M revenue and -$40.2M net income in fiscal year 2024, the period ended 2024-12-31. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $13.4M and net income was -$3.9M, versus $9.6M revenue and -$10.2M net income in fiscal Q2 2025, the quarter ended 2025-06-30. Still, trailing free cash flow is -$38.6M, a -9.3% FCF yield, so cash burn remains real. The balance sheet has low debt—D/E of 0.01—and an Altman Z-Score of 7.37, but that does not replace profits. At the 2026-10-13 close of $20.34, FairStock calculates P/B of 1.32, a Graham Number of $20.73, and only 1.88% margin of safety. It also shows P/E of 16.40 on EPS of $1.24, yet filed diluted EPS are negative: -$0.55 in fiscal year 2025, the period ended 2025-12-31, and -$0.20 in fiscal Q2 2026, the quarter ended 2026-06-30. FairStock Score is 57/100 and Piotroski is 4/9. I see no durable moat and no bargain. The investment case rests on clinical data and financing, not on proven earning power.

In plain English: Assembly Biosciences is a small biotech company working on antiviral medicines for herpes and hepatitis delta. It still loses money, but its sales have grown and its losses have narrowed recently. At $20.34 a share, the price looks roughly fair compared with its assets and simple value measures, not clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer